152 related articles for article (PubMed ID: 25105184)
1. FDA approves Dalvance to treat skin infections.
Clin Infect Dis; 2014 Jul; 59(2):i. PubMed ID: 25105184
[No Abstract] [Full Text] [Related]
2. Dalbavancin (Dalvance) for the treatment of acute bacterial skin infection.
Gupta AK; Foley KA; Abramovits W; Rosen T
Skinmed; 2014; 12(6):366-9. PubMed ID: 25823083
[No Abstract] [Full Text] [Related]
3. Dalbavancin approved for acute skin infections.
Traynor K
Am J Health Syst Pharm; 2014 Jul; 71(13):1062. PubMed ID: 24939490
[No Abstract] [Full Text] [Related]
4. First vanguard anti-MRSA agent approved.
Fox JL
Nat Biotechnol; 2014 Jul; 32(7):603. PubMed ID: 25004211
[No Abstract] [Full Text] [Related]
5. Antimicrobial development in the era of emerging resistance.
Sorlozano A; Carrasco C; Cabeza J; Villegas E; Gutierrez J
Mini Rev Med Chem; 2009 Jul; 9(8):938-55. PubMed ID: 19601889
[TBL] [Abstract][Full Text] [Related]
6. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.
Beresford E; Biek D; Jandourek A; Mawal Y; Riccobene T; Friedland HD
Expert Rev Clin Pharmacol; 2014 Mar; 7(2):123-35. PubMed ID: 24494793
[TBL] [Abstract][Full Text] [Related]
7. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections.
Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
Nurse Pract; 2018 Oct; 43(10):31-37. PubMed ID: 30153191
[TBL] [Abstract][Full Text] [Related]
8. Antibiotics.
Dalal KS; Bridgeman MB
Nursing; 2017 Mar; 47(3):70. PubMed ID: 28225406
[No Abstract] [Full Text] [Related]
9. Three new agents added to the arsenal to fight MRSA.
Strain J
S D Med; 2014 Dec; 67(12):513-4. PubMed ID: 25571620
[No Abstract] [Full Text] [Related]
10. Current and emerging drugs for acute bacterial skin and skin structure infections: an update.
Kollipara R; Downing C; Lee M; Guidry J; Curtis S; Tyring S
Expert Opin Emerg Drugs; 2014 Sep; 19(3):431-40. PubMed ID: 25146459
[TBL] [Abstract][Full Text] [Related]
11. Introduction: fusidic acid enters the United States.
Moellering RC; Corey GR; Grayson ML
Clin Infect Dis; 2011 Jun; 52 Suppl 7():S467-8. PubMed ID: 21546622
[No Abstract] [Full Text] [Related]
12. MRSA new treatments on the horizon: current status.
Wilcox MH
Injury; 2011 Dec; 42 Suppl 5():S42-4. PubMed ID: 22196910
[TBL] [Abstract][Full Text] [Related]
13. New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents.
Hahn AW; Jain R; Spach DH
Med Clin North Am; 2016 Jul; 100(4):911-26. PubMed ID: 27235621
[TBL] [Abstract][Full Text] [Related]
14. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good.
Corey GR; Stryjewski ME
Clin Infect Dis; 2011 Jun; 52 Suppl 7():S469-76. PubMed ID: 21546623
[TBL] [Abstract][Full Text] [Related]
15. Dalbavancin or oritavancin for skin infections.
Cormican M
N Engl J Med; 2014 Sep; 371(12):1161. PubMed ID: 25229925
[No Abstract] [Full Text] [Related]
16. Pharmacology and the treatment of complicated skin and skin-structure infections.
Chambers HF
N Engl J Med; 2014 Jun; 370(23):2238-9. PubMed ID: 24897088
[No Abstract] [Full Text] [Related]
17. Managing acute bacterial skin and skin structure infections: Focus on new lipoglycopeptides.
Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
Nurse Pract; 2017 May; 42(5):1-6. PubMed ID: 28406838
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin or oritavancin for skin infections.
Corey GR; Jiang H; Moeck G
N Engl J Med; 2014 Sep; 371(12):1162-3. PubMed ID: 25243251
[No Abstract] [Full Text] [Related]
19. Dalbavancin or oritavancin for skin infections.
Baang J; Fisher S
N Engl J Med; 2014 Sep; 371(12):1160-1. PubMed ID: 25229924
[No Abstract] [Full Text] [Related]
20. Dalbavancin or oritavancin for skin infections.
Núñez-Núñez M; Rodríguez-Baño J
N Engl J Med; 2014 Sep; 371(12):1160. PubMed ID: 25229923
[No Abstract] [Full Text] [Related]
[Next] [New Search]
